New weekly shot challenges semaglutide for diabetes and weight loss
NCT ID NCT06184568
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 study tested a new drug called IBI362 (mazdutide) against the well-known semaglutide in 349 Chinese adults with early type 2 diabetes and obesity. Participants received weekly injections for 32 weeks, with some continuing for an extra 24 weeks. The main goal was to see how many people achieved both good blood sugar control (HbA1c below 7%) and significant weight loss (at least 10%).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI362 (mazdutide) and semaglutide
- What this could lead to
- If IBI362 works better than semaglutide, it could offer a new once-weekly injection option for people with early type 2 diabetes and obesity to better control blood sugar and lose weight.
- What could go wrong
- This is a completed Phase 3 trial, but results are not yet published. The study only included Chinese participants, so findings may not apply to other populations. Side effects from these drugs can include nausea, vomiting, and diarrhea.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100010, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personality type may influence diabetic wound healing – a study investigates
- Timing your meals or halving your rice: a new trial tests simple diet hacks for weight loss and blood sugar control
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Can a strong support network help people with diabetic kidney disease take better care of themselves?
- Can a new drug boost Semaglutide's power against diabetes and obesity?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?